S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
CGC   21.27 (+14.05%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.71 (-1.58%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
AMD   38.91 (-1.82%)
ACB   2.61 (+7.40%)
GILD   66.93 (-0.22%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
CGC   21.27 (+14.05%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.71 (-1.58%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
AMD   38.91 (-1.82%)
ACB   2.61 (+7.40%)
GILD   66.93 (-0.22%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
CGC   21.27 (+14.05%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.71 (-1.58%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
AMD   38.91 (-1.82%)
ACB   2.61 (+7.40%)
GILD   66.93 (-0.22%)
S&P 500   3,135.96 (-0.32%)
DOW   27,909.60 (-0.38%)
QQQ   204.07 (-0.45%)
AAPL   266.92 (-1.40%)
MSFT   151.36 (-0.26%)
GOOGL   1,342.99 (+0.27%)
CGC   21.27 (+14.05%)
NVDA   212.17 (+0.00%)
MU   46.45 (-3.09%)
BABA   198.71 (-1.58%)
GE   10.99 (-0.99%)
TSLA   339.53 (+1.08%)
AMD   38.91 (-1.82%)
ACB   2.61 (+7.40%)
GILD   66.93 (-0.22%)
Log in

KITOV PHARMA LT/S News Headlines (NASDAQ:KTOV)

$0.72
0.00 (0.00 %)
(As of 12/9/2019 04:00 PM ET)
Today's Range
$0.70
Now: $0.72
$0.72
50-Day Range
$0.70
MA: $0.73
$0.81
52-Week Range
$0.56
Now: $0.72
$2.92
Volume17,653 shs
Average Volume40,231 shs
Market Capitalization$14.06 million
P/E Ratio1.85
Dividend YieldN/A
Beta3.55

Headlines

KITOV PHARMA LT/S (NASDAQ KTOV) News Headlines

Source:
DateHeadline
-$0.13 Earnings Per Share Expected for KITOV PHARMA LT/S (NASDAQ:KTOV) This Quarter-$0.13 Earnings Per Share Expected for KITOV PHARMA LT/S (NASDAQ:KTOV) This Quarter
www.americanbankingnews.com - December 1 at 6:47 AM
Kitov Pharma Ltd. American Depositary Shares (KTOV) SEC FilingsKitov Pharma Ltd. American Depositary Shares (KTOV) SEC Filings
www.nasdaq.com - November 10 at 10:52 PM
Kitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi™ in the U.SKitov Pharma Announces Amended Marketing and Distribution Agreement with Coeptis and Provides Update on the Upcoming Launch of Consensi™ in the U.S
finance.yahoo.com - October 11 at 1:35 PM
Kitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its BoardKitov Pharma Appoints Eric K. Rowinsky, M.D., as Chairman of its Board
finance.yahoo.com - October 2 at 5:14 PM
Kitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare ConferenceKitov Pharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference
finance.yahoo.com - September 3 at 10:54 AM
Kitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care ConferenceKitov Pharma to Present New Data on NT-219 Targeting Cancer Drug Resistance at the AACR Pancreatic Cancer: Advances in Science and Clinical Care Conference
finance.yahoo.com - August 29 at 10:44 AM
Kitov Pharma Announces Significant Progress in Closing of FameWave Acquisition DealKitov Pharma Announces Significant Progress in Closing of FameWave Acquisition Deal
finance.yahoo.com - August 16 at 9:38 AM
Administrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities AuthorityAdministrative Enforcement Agreement Finalized between Kitov Pharma and the Israeli Securities Authority
finance.yahoo.com - August 14 at 9:11 AM
Kitov Pharma Reports First Half 2019 Financial Results and Provides Business UpdateKitov Pharma Reports First Half 2019 Financial Results and Provides Business Update
finance.yahoo.com - August 8 at 10:56 AM
Kitov receives notice regarding minimum bid requirementsKitov receives notice regarding minimum bid requirements
seekingalpha.com - July 15 at 9:54 AM
Kitov Receives Nasdaq Notification Regarding Minimum Bid RequirementsKitov Receives Nasdaq Notification Regarding Minimum Bid Requirements
finance.yahoo.com - July 12 at 5:18 PM
Kitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck CancersKitov Successfully Completes IND-enabling Studies to advance NT219 for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancers
finance.yahoo.com - June 27 at 10:01 AM
Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi(TM)Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi(TM)
www.marketwatch.com - May 10 at 5:39 PM
Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi™Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi™
finance.yahoo.com - May 10 at 9:50 AM
Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED ConferenceKitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference
finance.yahoo.com - May 9 at 9:49 AM
Kitov Announces Retirement of Founder and Executive Chairman Dr. Paul WaymackKitov Announces Retirement of Founder and Executive Chairman Dr. Paul Waymack
finance.yahoo.com - May 2 at 6:08 PM
Kitovs Acquisition Of FameWave Marks Transition Into OncologyKitov's Acquisition Of FameWave Marks Transition Into Oncology
seekingalpha.com - April 16 at 10:48 AM
Kitov up 20% on Famewave/BMY collaborationKitov up 20% on Famewave/BMY collaboration
seekingalpha.com - April 12 at 5:28 PM
FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 TrialFameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial
www.nasdaq.com - April 12 at 10:26 AM
FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®)FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®)
finance.yahoo.com - April 12 at 10:26 AM
Kitov Announces Key Milestone in FameWave AcquisitionKitov Announces Key Milestone in FameWave Acquisition
finance.yahoo.com - April 12 at 10:26 AM
Kitov Pharma Ltd. Estimate MomentumKitov Pharma Ltd. Estimate Momentum
www.nasdaq.com - March 21 at 8:12 AM
Potential Milestones Coming for Kitov Pharma and Product Commercialization PlansPotential Milestones Coming for Kitov Pharma and Product Commercialization Plans
finance.yahoo.com - March 18 at 9:33 AM
Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology CompanyKitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company
finance.yahoo.com - March 14 at 10:27 AM
Kitov Pharma Reports Year End 2018 Financial Results and Provides Business UpdateKitov Pharma Reports Year End 2018 Financial Results and Provides Business Update
finance.yahoo.com - February 7 at 9:47 AM
Form 6-K Kitov Pharma Ltd. For: Jan 18 - StreetInsider.comForm 6-K Kitov Pharma Ltd. For: Jan 18 - StreetInsider.com
www.streetinsider.com - January 20 at 5:29 PM
Kitov Updates Investors On NT-219 And Sends The Stock Parabolic, I Provide Reasons For Investors To HoldKitov Updates Investors On NT-219 And Sends The Stock Parabolic, I Provide Reasons For Investors To Hold
seekingalpha.com - January 18 at 8:09 PM
Kitov Closes $6 Million Registered Direct OfferingKitov Closes $6 Million Registered Direct Offering
finance.yahoo.com - January 18 at 8:09 PM
New Data on Kitovs NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect - GlobeNewswireNew Data on Kitov's NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect - GlobeNewswire
globenewswire.com - January 17 at 5:02 PM
Form SC 13G Kitov Pharma Ltd. Filed by: SABBY MANAGEMENT, LLC - StreetInsider.comForm SC 13G Kitov Pharma Ltd. Filed by: SABBY MANAGEMENT, LLC - StreetInsider.com
www.streetinsider.com - January 17 at 5:02 PM
Kitov Pharmas Stock Up on Anti-Cancer Candidate FindingsKitov Pharma's Stock Up on Anti-Cancer Candidate Findings
www.zacks.com - January 16 at 4:52 PM
4 Healthcare Stocks Seeing Gains On Wednesday (1/16/19)4 Healthcare Stocks Seeing Gains On Wednesday (1/16/19)
finance.yahoo.com - January 16 at 4:52 PM
Kitov Announces Pricing of $6 Million Registered Direct OfferingKitov Announces Pricing of $6 Million Registered Direct Offering
finance.yahoo.com - January 16 at 4:52 PM
Thinking about buying stock in Aurora Cannabis Inc, Goodyear Tire & Rubber, Kitov Pharma, PG&E Corp or VirnetX?Thinking about buying stock in Aurora Cannabis Inc, Goodyear Tire & Rubber, Kitov Pharma, PG&E Corp or VirnetX?
www.marketwatch.com - January 16 at 9:40 AM
SSYS, ARRY among premarket gainersSSYS, ARRY among premarket gainers
seekingalpha.com - January 15 at 9:38 AM
New Data on Kitov’s NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer EffectNew Data on Kitov’s NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect
finance.yahoo.com - January 15 at 9:38 AM
Kitov Secures Consensi Commercial Deal With CoeptisKitov Secures Consensi Commercial Deal With Coeptis
seekingalpha.com - January 7 at 5:10 PM
Kitov +40% on signing marketing agreement with Coeptis Pharmaceuticals for ConsensiKitov +40% on signing marketing agreement with Coeptis Pharmaceuticals for Consensi
seekingalpha.com - January 3 at 9:52 AM
Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis PharmaceuticalsKitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis Pharmaceuticals
finance.yahoo.com - January 3 at 9:52 AM
4 Healthcare Stocks Gaining Speed on Thursday (1/3/19)4 Healthcare Stocks Gaining Speed on Thursday (1/3/19)
finance.yahoo.com - January 3 at 9:52 AM
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of American Depository Shares and Warrants of Kitov Pharmaceuticals Holdings, Ltd. -- KTOVPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of American Depository Shares and Warrants of Kitov Pharmaceuticals Holdings, Ltd. -- KTOV
finance.yahoo.com - October 15 at 9:19 AM
Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial OfficerKitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer
finance.yahoo.com - October 11 at 9:12 AM
Kitov to Present Data on NT219 in Combination with Keytruda® and Erbitux® at AACR International Cancer Immunotherapy ConferenceKitov to Present Data on NT219 in Combination with Keytruda® and Erbitux® at AACR International Cancer Immunotherapy Conference
finance.yahoo.com - September 26 at 9:51 AM
Kitov Pharma Updates on Motions in USA Initiated by Kitov ChairmanKitov Pharma Updates on Motions in USA Initiated by Kitov Chairman
finance.yahoo.com - September 18 at 4:11 PM
Kitov Pharma Provides Corporate Update and Reports First Half 2018 Financial ResultsKitov Pharma Provides Corporate Update and Reports First Half 2018 Financial Results
finance.yahoo.com - August 29 at 9:56 AM
Kitov Announces Settlement of Shareholder Class Action LitigationKitov Announces Settlement of Shareholder Class Action Litigation
finance.yahoo.com - July 30 at 4:11 PM
Kitov to Host Business Update Conference Call on Monday, July 2Kitov to Host Business Update Conference Call on Monday, July 2
finance.yahoo.com - June 27 at 11:49 AM
Kitov Announces Positive Pre-clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor EfficacyKitov Announces Positive Pre-clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor Efficacy
finance.yahoo.com - June 26 at 11:27 AM
Kitov Pharma (KTOV) Reports Positive Pre-clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor EfficacyKitov Pharma (KTOV) Reports Positive Pre-clinical Data from NT219 Demonstrating its Dose-Dependent Anti-Tumor Efficacy
www.streetinsider.com - June 16 at 8:51 AM
The FDA Just Approved Kitovs Consensi - Now What?The FDA Just Approved Kitov's Consensi - Now What?
seekingalpha.com - June 11 at 4:20 PM
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Featured Article: Bear Market

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel